Wed, 24/06/09 – 7:42 | No Comment

Amicus Therapeutics (Nasdaq: FOLD) announced it has commenced the U.S. registration Phase 3 trial with its investigational drug, Amigal(TM) (migalastat hydrochloride) for the treatment of Fabry disease. The Company has reached agreement with the …

Read the full story »
Aim to Cure

A focus on disease-specific efforts by pharmaceutical and biotech companies

Analysis

Read in depth analysis by industry experts on investing opportunities and business strategies

Company Profiles

Learn about corporate strategies, positioning and investing opportunities

Industry News

Stay on top of the industry with our industry news bulletin

Mutual Funds

Diversify to hedge your investment during economic turbulence

Home » Archive by Category

Articles in Featured

Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) For The Treatment Of Fabry Disease
Wednesday, 24 Jun, 2009 – 7:42 | No Comment

Amicus Therapeutics (Nasdaq: FOLD) announced it has commenced the U.S. registration Phase 3 trial with its investigational drug, Amigal(TM) (migalastat hydrochloride) for the treatment of Fabry disease. The Company has reached agreement with the …

New Vaccine From Intervet/Schering-Plough Animal Health Is First For Canine Influenza Virus
Wednesday, 24 Jun, 2009 – 3:00 | No Comment

Intervet/Schering-Plough Animal Health, the global leader in veterinary biologicals, announced the availability of the first vaccine against canine influenza virus (CIV), which was granted a conditional product license by the U.S. Department of Agriculture (USDA) …

HCPC Calls For Greater Healthcare Savings Through Improved Adherence To Prescription Drug Regimens
Wednesday, 24 Jun, 2009 – 3:00 | No Comment

With today’s announcement that the Pharmaceutical Research and Manufacturers of America (PhRMA) has offered to voluntarily grant some $80 billion in discounts to Medicare beneficiaries over the next decade in an effort to reduce overall …

NUCYNTA(TM) (tapentadol) CII Immediate Release Tablets Now Available For Relief Of Moderate To Severe Acute Pain
Wednesday, 24 Jun, 2009 – 3:00 | No Comment

Patients suffering from acute pain and healthcare professionals who treat pain have a new treatment option: NUCYNTA(TM) (tapentadol) CII immediate release tablets. This new medication for the relief of moderate to severe acute pain in …

Also In Global Health News: Venezuela Voids Pharma Patents; Namibia Sanitation; Mapping Disease With Satellites; Zimbabwe Health Funding
Tuesday, 23 Jun, 2009 – 5:00 | No Comment

Venezuela To Void Some Pharmaceutical Patents Commerce Minister Eduardo Saman on Saturday said Venezuela plans to void some pharmaceutical patents and allow domestic manufacturers to produce licensed …

WorldCare Clinical Implements MCC’s Imaging Performance Metrics In Support Of Standardized Peformance For Imaging Trials
Tuesday, 23 Jun, 2009 – 4:00 | No Comment

45th DIA Annual Meeting — Booth # 1501 — WorldCare Clinical, LLC (WCC), a leading imaging CRO for clinical trials in the pharmaceutical, biotechnology and medical device industries, announced that it is offering version 1.0 …

Lytix Biopharma And KAEL-GemVax Announce Joint Clinical Trial To Combine LTX-315 And GV1001 Cancer Immunotherapy
Saturday, 20 Jun, 2009 – 0:00 | No Comment

The Norwegian biopharmaceutical company Lytix Biopharma and Korean company KAEL-GemVax announced the signing of a collaborative agreement to test lead compounds LTX-315 and GV1001 as a combination therapy for the treatment of cancer. …

Cephalon Provides Clinical Update On Lestaurtinib In Relapsed Acute Myelogenous Leukemia
Saturday, 20 Jun, 2009 – 0:00 | No Comment

Cephalon, Inc. (Nasdaq: CEPH) announced results from a pivotal clinical trial of lestaurtinib (CEP-701) in patients with relapsed acute myelogenous leukemia (AML) expressing FLT3 activating mutations. The study was designed to show the benefit …

Helix BioPharma To Present L-DOS47 Analytical Method Development Findings At 2009 AAPS National Biotechnology Conference
Saturday, 20 Jun, 2009 – 0:00 | No Comment

Helix BioPharma Corp. (TSX, FSE: HBP) announced that Dr. Heman Chao, chief scientific officer at Helix BioPharma Corp., will be presenting a scientific poster describing L-DOS47 analytical method development findings at the 2009 American Association …

BIO Commends Senate Committee On Small Business And Entrepreneurship’s SBIR Reauthorization
Friday, 19 Jun, 2009 – 7:00 | No Comment

Under legislation reported by the Senate Committee on Small Business and Entrepreneurship, small companies that receive the majority of their financing from venture capital will once again be considered eligible to compete for Small Business …

Sanofi-Aventis, GlaxoSmithKline Will Donate Influenza Vaccines To WHO
Friday, 19 Jun, 2009 – 5:00 | No Comment

The drugmaker Sanofi-Aventis will donate millions of doses of a vaccine that offers protection against the H1N1 (swine flu) virus to the WHO once the vaccine is ready, the company’s chief executive officer announced Tuesday, …

Zysolin(TM) Pre-clinical Data Supports Once-a-day Dosing In Humans
Friday, 19 Jun, 2009 – 3:00 | No Comment

AlphaRx (OTC BB:ALRX) is pleased to report a significant breakthrough in the development of Zysolin(TM), an inhaled Tobramycin nanoparticle formulation utilizing the company’s proprietary drug delivery platform, and intended for the adjunctive treatment of Pseudomonas …

Unique Collaboration Between TB Alliance And Tibotec To Accelerate Tuberculosis Drug Development
Friday, 19 Jun, 2009 – 3:00 | No Comment

A new landmark collaboration between the Global Alliance for TB Drug Development (TB Alliance), a not-for-profit, product development partnership, and Tibotec Inc., (Tibotec), a global pharmaceutical company, has been announced at the Pacific Health Summit …

New Biological Therapy Ilaris(R) Approved In US To Treat Children And Adults With CAPS, A Serious Life-Long Auto-Inflammatory Disease
Friday, 19 Jun, 2009 – 2:00 | No Comment

The U.S. Food and Drug Administration (FDA) has approved Ilaris(R) (canakinumab) for the treatment of children and adults with cryopyrin-associated periodic syndrome (CAPS), which includes a number of rare, but life-long, auto-inflammatory disorders with debilitating …

Matthew Lehman Of SPRI Clinical Trials Speaks On Designing Trials For Success At The Trout Group Investor Relations Seminar
Friday, 19 Jun, 2009 – 2:00 | No Comment

In designing and conducting clinical trials, it is critical to meet FDA objectives while preventing program “drift,” according to Matthew Lehman, chief operating officer of SPRI Clinical Trials-Global, LLC in his remarks at a recent …

Transatlantic Co-Operation Leads To Major Scientific CMOS (sCMOS) Technology Breakthrough
Thursday, 18 Jun, 2009 – 7:00 | No Comment

CMOS image sensor (CIS) technology stands on the brink of fulfilling its potential to become the global detector platform of choice for scientific photonics applications that require world class performance in the fields of sensitivity, …

House Bill May Target Drugmakers’ Advertising Tax Breaks
Thursday, 18 Jun, 2009 – 5:00 | No Comment

Rep. Charles Rangel, D-N.Y., says the House Ways and Means Committee may seek to raise money for health reform by imposing a $37 billion tax on drugmaker’s advertisements, Bloomberg reports: “As lawmakers seek ways to …

Xanodyne Receives Approval From The U.S. Food And Drug Administration For ZIPSOR(TM) (diclofenac Potassium) Liquid Filled Capsules
Thursday, 18 Jun, 2009 – 2:00 | No Comment

Xanodyne Pharmaceuticals, Inc. announced that it has received approval from the U.S. Food and Drug Administration (FDA) for Zipsor (diclofenac potassium) Liquid Filled Capsules, a new treatment option indicated for relief of mild to moderate …

CuraGen Announces Expansion Of CR011-vcMMAE Phase II Trial In Advanced Breast Cancer
Thursday, 18 Jun, 2009 – 2:00 | No Comment

CuraGen Corporation (Nasdaq: CRGN) announced that its Phase I/II Trial evaluating CR011-vcMMAE for the treatment of patients with advanced breast cancer has met the efficacy criteria for advancement to the second stage of enrollment. …

Epeius Biotechnologies’ Rexin-G Receives FDA Fast Track Designation For The Treatment Of Pancreatic Cancer
Thursday, 18 Jun, 2009 – 2:00 | No Comment

Epeius Biotechnologies announced that its lead product, Rexin-G, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for use as a second-line treatment for advanced or metastatic pancreatic cancer. The …